指南与共识系统性红斑狼疮

系统性红斑狼疮更新治疗推荐背后证据的质量评价

Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus.
指南 / 共识 · Rheumatology (Oxford) · 2021-01-01

本研究梳理EULAR、BSR和PANLAR最新SLE治疗推荐所引用的250项研究,发现72%为前瞻性或回顾性队列,仅28%为随机对照试验,纳入患者数中位37例,提示高质量证据稀缺。作者呼吁采用2019年SLE诊断标准开展设计良好的大规模研究。

要点

  • SLE治疗推荐引用的证据以队列研究为主,随机对照试验仅占28%。
  • 纳入研究患者数中位仅37例,多数研究把握度不足。
  • 仅15%的研究在定义研究人群时使用了疾病活动度评分。

核心结论

  • 新近发布的SLE治疗指南所引用的高质量、把握度充分的研究稀缺。
  • 需要采用2019年SLE诊断标准开展设计良好的大规模研究以更好指导临床。

研究设计与样本

  • 从新近发布的EULAR、BSR和PANLAR SLE治疗推荐中汇编参考文献。
  • 排除患者少于10例及未说明SLE诊断标准的研究后,共纳入250项研究。

主要发现

  • 前瞻性和回顾性队列研究占72%,随机对照试验仅占28%。
  • 纳入患者数中位数(四分位距)为37(19-86)例。
  • 修订版ACR 1982标准是最常用的SLE诊断标准(52%),其次为修订版ACR 1997标准(27%)。
  • 仅15%的研究在定义研究人群时使用了疾病活动度评分。

关键数值与推荐

  • SLE诊断标准使用比例:修订版ACR 1982标准52%,修订版ACR 1997标准27%。
  • 研究设计构成:前瞻性和回顾性队列72%,随机对照试验28%。
  • 纳入患者数中位数(四分位距)37(19-86)例。
  • 使用疾病活动度评分定义研究人群的研究占15%。

临床怎么用

  • 临床解读SLE治疗推荐时应意识到其背后随机对照证据有限。
  • 关注推荐意见所依据的研究规模与诊断标准,判断证据强度。

局限性

  • 仅评价指南引用的研究,未纳入未引用文献。
  • 排除患者少于10例及未说明SLE诊断标准的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: SLE is a multisystem autoimmune disorder known for its broad clinical spectrum. Recently, the European, British and Latin American rheumatology professional societies [EULAR, British Society for Rheumatology (BSR) and Pan-American League of Associations of Rheumatology (PANLAR)] published updated recommendations for SLE management. The objective of this study was to characterize the data supporting the updated recommendations, with the goal of highlighting areas that could benefit from additional high-quality research. METHODS: References were compiled from the recently published EULAR, BSR and PANLAR SLE treatment recommendations. Data collected from each study included publication year, treatment regimen, study design, sample size, inclusion and exclusion criteria and relevant SLE diagnostic criteria. Studies with less than 10 patients and those that did not specify the SLE diagnostic criteria used were excluded. RESULTS: Altogether, 250 studies were included in this study. The majority were prospective and retrospective cohorts (72%), with only a small percentage of randomized controlled trials (28%). The median (interquartile range) number of patients included was 37 (19-86). The revised ACR 1982 criteria were the most commonly used criteria for SLE diagnosis (52%), followed by the revised ACR criteria from 1997 (27%). Only a small proportion of studies included the use of disease activity scores when defining study population (15%). CONCLUSION: Our study has indicated a scarcity of sufficiently powered high-quality research referenced in the recently published SLE treatment guidelines. Well-designed large-scale studies utilizing the updated 2019 SLE diagnostic criteria are needed to better inform healthcare professionals caring for patients with SLE.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yavne Y, Edel Y, Berman J, et al. Quality evaluation of the underlying evidence in the updated treatment recommendations for systemic lupus erythematosus. Rheumatology (Oxford). 2021. PMID: 33764408. doi:10.1093/rheumatology/keab306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。